New medical treatments for endometriosis

被引:73
作者
Olive, DL [1 ]
Lindheim, SR [1 ]
Pritts, EA [1 ]
机构
[1] Univ Wisconsin, Sch Med, Dept Obstet & Gynecol, Madison, WI 53792 USA
关键词
endometriosis; experimental; immunologic; medical;
D O I
10.1016/j.bpobgyn.2004.03.005
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The medical treatment of endometriosis has long centered upon producing a hypoestrogenic environment by producing pituitary suppression or a progestin-dominant environment. However, as more is uncovered regarding the pathogenesis and pathophysiology of this disease, more targeted therapies can be developed. Current research has focused upon medications designed to attack specific aspects of the development and maintenance of endometriosis. These include progesterone receptor modulators, gonadotropin releasing hormone (GnRH) antagonists, aromatase inhibitors, tumor necrosis factor alpha (TNF-alpha) inhibitors, angiogenesis inhibitors, matrix metalloproteinase inhibitors, pentoxifylline (and other general immune modulators), and estrogen receptor beta agonists. It is hoped that this new wave of medications will improve the response to medical therapy for this disorder.
引用
收藏
页码:319 / 328
页数:10
相关论文
共 32 条
[1]   Effect of interferon α-2b on endometrioma cells in vitro [J].
Badawy, SZA ;
Etman, A ;
Cuenca, V ;
Montante, A ;
Kaufman, L .
OBSTETRICS AND GYNECOLOGY, 2001, 98 (03) :417-420
[2]   Pentoxifylline versus placebo in the treatment of infertility associated with minimal or mild endometriosis: a pilot randomized clinical trial [J].
Balasch, J ;
Creus, M ;
Fabregues, F ;
Carmona, F ;
MartinezRoman, S ;
Manau, D ;
Vanrell, JA .
HUMAN REPRODUCTION, 1997, 12 (09) :2046-2050
[3]  
Barcz E, 2001, Ginekol Pol, V72, P442
[4]   Molecular basis for treating endometriosis with aromatase inhibitors [J].
Bulun, SE ;
Zeitoun, KM ;
Takayama, K ;
Sasano, H .
HUMAN REPRODUCTION UPDATE, 2000, 6 (05) :413-418
[5]   Aromatase in aging women [J].
Bulun, SE ;
Zeitoun, K ;
Sasano, H ;
Simpson, ER .
SEMINARS IN REPRODUCTIVE ENDOCRINOLOGY, 1999, 17 (04) :349-358
[6]   Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium [J].
Chwalisz, K ;
Brenner, RM ;
Fuhrmann, UU ;
Hess-Stumpp, H ;
Elger, W .
STEROIDS, 2000, 65 (10-11) :741-751
[7]   Recombinant human TNF binding protein-1 (r-hTBP-1) inhibits the development of endometriosis in baboons: a prospective, randomized, placebo- and drug-controlled study. [J].
D'Hooghe, TM ;
Cuneo, S ;
Nugent, N ;
Chai, D ;
Deer, F ;
Mwenda, J .
FERTILITY AND STERILITY, 2001, 76 (03) :S1-S1
[8]   Vascular endothelial growth factor (VEGF) in endometriosis [J].
Donnez, J ;
Smoes, P ;
Gillerot, S ;
Casanas-Roux, F ;
Nisolle, M .
HUMAN REPRODUCTION, 1998, 13 (06) :1686-1690
[9]   Endocrine pharmacological characterization of progesterone antagonists and progesterone receptor modulators with respect to PR-agonistic and antagonistic activity [J].
Elger, W ;
Bartley, J ;
Schneider, B ;
Kaufmann, G ;
Schubert, G ;
Chwalisz, K .
STEROIDS, 2000, 65 (10-11) :713-723
[10]   High concentrations of the vascular endothelial growth factor and interleukin-8 in ovarian endometriomata [J].
Fasciani, A ;
D'Ambrogio, G ;
Bocci, G ;
Monti, M ;
Genazzani, AR ;
Artini, PG .
MOLECULAR HUMAN REPRODUCTION, 2000, 6 (01) :50-54